https://orcid.org/0000-0001-8756-1190
References
- Wang JGL, Xu YN. Risk factor analysis of respiratory tract infection in elderly patients in a tertiary grade A hospital cadre ward. Med J Chin PLA. 2020;38(8):41–43.
- Abreu C, Rocha-Pereira N, Sarmento A, Magro F. Nocardia infections among immunomodulated inflammatory bowel disease patients: a review. World J Gastroenterol. 2015;21(21):6491–6498. doi:10.3748/wjg.v21.i21.6491
- Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
- Lagrou K, Chen S, Masur H, et al. Pneumocystis jirovecii disease: basis for the revised EORTC/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus. Clin Infect Dis. 2021;72(Suppl 2):S114–S120. doi:10.1093/cid/ciaa1805
- Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64(6):e34–e65. doi:10.1093/cid/ciw861
- Karageorgopoulos DE, Qu JM, Korbila IP, Zhu YG, Vasileiou VA, Falagas ME. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2013;19(1):39–49. doi:10.1111/j.1469-0691.2011.03760.x
- Theel ES, Jespersen DJ, Iqbal S, et al. Detection of (1, 3)-beta-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;175(1–2):33–41. doi:10.1007/s11046-012-9579-y
- Morjaria S, Frame J, Franco-Garcia A, Geyer A, Kamboj M, Babady NE. Clinical performance of (1,3) Beta-D glucan for the diagnosis of pneumocystis pneumonia (PCP) in cancer patients tested with PCP polymerase chain reaction. Clin Infect Dis. 2019;69(8):1303–1309. doi:10.1093/cid/ciy1072
- Sax PE, Komarow L, Finkelman MA, et al. Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2011;53(2):197–202. doi:10.1093/cid/cir335
- Hou J, Cao J, Tan P, Yu Y. Pneumocystis jiroveci pneumonia, Nocardia brasiliensis, and Mycobacterium tuberculosis co-infection in a myasthenia gravis patient: a case report. Medicine. 2021;100(1):e24245. doi:10.1097/MD.0000000000024245
- Restrepo A, Clark NM. Infectious diseases community of practice of the American Society of T. Nocardia infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019;33(9):e13509. doi:10.1111/ctr.13509
- John G, Bartlett PGA, Paul A. The Johns Hopkins ABX Guide. Beijing: Scientific and Technical Documentation Press; 2012.
- Cercenado E, Marin M, Sanchez-Martinez M, Cuevas O, Martinez-Alarcon J, Bouza E. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrob Agents Chemother. 2007;51(3):1102–1104. doi:10.1128/AAC.01102-06
- David N, Gilbert HFC, Michael S. The Sanford Guide to Antimicrobial Therapy 2020. 50 ed. Beijing: PEKING UNION MEDICAL COLLEGE PRESS; 2021.
- Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080–1087. doi:10.1093/cid/cis599
- John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15(11):881–895. doi:10.1080/17425255.2019.1671971
- Chen K, Zhang X, Ke X, Du G, Yang K, Zhai S. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. Ther Drug Monit. 2018;40(6):663–674. doi:10.1097/FTD.0000000000000561